Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas

Genetically modified T-cell immunotherapies are revolutionizing the therapeutic options for hematological malignancies, especially those of B-cell origin. Impressive efficacies of CD19-directed chimeric antigen receptor (CAR)-T therapy have been reported in refractory/relapsed (R/R) B-cell non-Hodgk...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Hao, Li, Ningwen, Wang, Gaoxiang, Cao, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083339/
https://www.ncbi.nlm.nih.gov/pubmed/37051246
http://dx.doi.org/10.3389/fimmu.2023.1110028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083339/
https://www.ncbi.nlm.nih.gov/pubmed/37051246
http://dx.doi.org/10.3389/fimmu.2023.1110028

Ejemplares similares